Kiniksa (KNSA) | Stock Overview & Key Data

Kiniksa Pharmaceuticals, Ltd. | Healthcare

$26.89

3.62%

| Kiniksa Stock Comparison:

Kiniksa vs Zoetis Kiniksa vs Haleon Plc - ADR Kiniksa vs Supernus Kiniksa vs BGM Kiniksa vs Bausch Health Kiniksa vs S&P 500 | Market

Kiniksa Performance Comparison

Loading chart data...

Kiniksa

Healthcare Sector

S&P 500

View Full Price History

Stock Range

Today's Range

Low: $25.70 High: $27.03

on May 23, 2025

52 Week Range

Low: $17.38 High: $28.56

on July 1, 2024

on May 5, 2025

All-Time High: $32.88 on September 17, 2018

Key Statistics

Market Cap i $1.9B

EPS i -0.24

P/E Ratio (TTM) i 164.31

Forward P/E i 47.23

P/B Ratio i 4.13

PEG Ratio i 47.23

Div. Yield i 0.00%

ROE i -3.81%

Beta i 0.065

Debt to Equity i 2.17

Financial Highlights

Profitability

Gross Margin i 55.25%

Operating Margin i 9.63%

Profit Margin i -3.52%

Returns and Earnings

Return on Assets (TTM) i -1.77%

Return on Equity (TTM) i -3.81%

EBITDA i $-14.2M

Net Income (TTM) i $-17.0M

Growth

Revenue (TTM) i

Revenue Per Share (TTM) i

Quarterly Revenue Growth i

Quarterly Earnings Growth i

Peer Performance Comparison

Company	Market Cap	1W	1M	3M	6M	YTD	1Y	3Y	5Y
Kiniksa KNSA	1.90B Small-cap	2.44%	28.78%	36.98%	23.35%	34.85%	41.21%	233.33%	28.89%
Zoetis ZTS	71.48B Large-cap	-0.28%	7.73%	-1.65%	-9.03%	-0.02%	-4.42%	-5.54%	16.62%
Haleon Plc - ADR HLN	49.99B Large-cap	3.15%	8.90%	9.75%	16.28%	18.01%	32.94%	50.34%	50.34%
Supernus SUPN	1.81B Small-cap	-3.98%	4.09%	-1.77%	-11.08%	-11.89%	16.54%	12.89%	32.92%
BGM BGM	2.27B Mid-cap	16.91%	34.99%	46.89%	108.24%	63.98%	234.10%	65.71%	-66.86%
Bausch Health BHC	1.66B Small-cap	-4.71%	-13.93%	-37.94%	-44.03%	-43.95%	-30.03%	-54.91%	-75.92%

Ownership & Short Interest

Insider Ownership i 3.82%

Institutional Ownership i 96.34%

Shares Short i 3M

Short Ratio i 4.58

Short % of Shares Outstanding i 8.54%

Average 10-Day Volume i 350K

Average 90-Day Volume i 608K

Kiniksa Recurring Investment / Dollar-Cost Averaging Calculator

Calculate how a regular investment in Kiniksa would have performed over time.

Investment Amount

Investment Frequency

Start Date

End Date (Optional)

If not specified, the latest available data will be used

Reinvest Dividends

Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.

Frequently Asked Questions

What is KNSA's 52-week high and low?

In the last 52 weeks, Kiniksa reached a high of $28.56 (on May 5, 2025) and a low of $17.38 (on July 1, 2024).

What is the market cap and P/E ratio for KNSA?

Curious about Kiniksa's size and valuation? Its market capitalization stands at 1.90B. When it comes to valuation, the P/E ratio (trailing twelve months) is 164.31, and the forward P/E (looking ahead) is 47.23.

Does KNSA pay dividends? If so, what's the yield?

As for dividends, Kiniksa isn't currently offering a significant yield, or that specific data isn't available right now. Its payout ratio, which shows how much of its earnings are paid as dividends, is 0.00%.

Who are Kiniksa's main competitors or similar companies to consider before investing?

When looking at Kiniksa, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:

Company	Mkt Cap	Sector	Industry	1Y Return	3Y Return
Zoetis ZTS	71.48B	Healthcare	Drug Manufacturers - Specialty & Generic	-4.42%	-5.54%
Haleon Plc - ADR HLN	49.99B	Healthcare	Drug Manufacturers - Specialty & Generic	32.94%	50.34%
Supernus SUPN	1.81B	Healthcare	Drug Manufacturers - Specialty & Generic	16.54%	12.89%
BGM BGM	2.27B	Healthcare	Drug Manufacturers - Specialty & Generic	234.10%	65.71%
Bausch Health BHC	1.66B	Healthcare	Drug Manufacturers - Specialty & Generic	-30.03%	-54.91%

For a more comprehensive list, please see the Peer Performance Comparison table on this page.

What are the key financial health indicators for Kiniksa Pharmaceuticals, Ltd.? (e.g., ROE, Debt/Equity)

To get a sense of Kiniksa's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is -3.81%, the Debt to Equity ratio from the most recent quarter is 2.17, and its Gross Profit Margin stands at 55.25%.

What is the recent revenue and earnings growth for KNSA?

Looking at Kiniksa's growth, its revenue over the trailing twelve months (TTM) was $481M. Compared to the same quarter last year (YoY), quarterly revenue grew by 72.50%, and quarterly earnings saw a YoY growth of 72.54%.

How much of KNSA stock is held by insiders and institutions?

Wondering who owns Kiniksa stock? Company insiders (like executives and directors) hold about 3.82% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 96.34%.

For more common questions about our data, please visit our About Data page.

Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.